Gut microbiota diversity (GMD)

Gut microbiota diversity refers to the variety, richness, and evenness of the trillions of microorganisms, including bacteria, archaea, fungi, and viruses, inhabiting the human gastrointestinal tract. While not a single molecular receptor or enzyme, it is increasingly treated as a systemic therapeutic target because a diverse microbial ecosystem is critical for metabolic health, immune education, and protection against pathogenic colonization. Low microbial diversity, or dysbiosis, is a hallmark of numerous conditions ranging from gastrointestinal disorders like Clostridioides difficile infection and Inflammatory Bowel Disease to systemic issues such as obesity, diabetes, and mood disorders. Therapeutic intervention involves modulating this diversity through various means: Fecal Microbiota Transplantation (FMT) and refined consortia-based biotherapeutics (e.g., SER-109) aim to physically replenish diversity, while prebiotics and dietary fibers selectively nourish beneficial species. Pharmacological agents, most notably antibiotics, can significantly impact diversity by depleting both pathogenic and commensal microbes. Monitoring changes in diversity via metagenomic sequencing and alpha-diversity indices serves as a key biomarker for clinical efficacy in microbiome-directed therapies.

Other names

Gut microbiome diversityIntestinal microbial diversityMicrobial alpha-diversityGut microbial richnessGastrointestinal microbiota diversity

Restoration of microbial ecological balance through introduction of diverse commensal species (Fecal Microbiota Transplantation/Probiotics), selective inhibition of pathogens (Narrow-spectrum antibiotics), or promotion of beneficial taxa growth (Prebiotics).